ERBB2 and breast cancer: In addition to the two approved ADCs mentioned above, trials are underway to evaluate numerous promising targets that are highly expressed in BC and can be designed into ADCs, such as Human Epidermal Growth Factor Receptor 2 (HER‐2) and SLIT and NTRK‐like family member 6 (SLITRK6).